Gynecologic oncology reports
Gynecologic oncology reports
Audio Summaries
Every issue of Gynecologic oncology reports moves the field forward, but reading every paper cover-to-cover isn't realistic. OSLR turns each article into a 3-minute audio summary so you can stay current while you commute, round, or work out.
Specialties
Gynecologic oncology reports covers research in these specialties.
Recent summaries
The latest articles summarized from Gynecologic oncology reports.
Comprehensive genomic profiling can improve diagnostic accuracy and Mullerian cancer treatment planning: A case report.
Nov 20, 2026
This case report asks whether paired tumor-normal whole-genome sequencing can resolve an ambiguous Müllerian primary site (ovarian versus uterine serous carcinoma) when histopathology is inconclusive. In a 57-year-old woman with peritoneal high-grade serous carcinoma, the CUPPA classifier predicted an endometrial primary with 99.6% probability, and WGS also identified a pathogenic germline MSH2 variant establishing Lynch syndrome. The authors conclude that genomic profiling can improve tumor assignment, inform treatment and trial eligibility, and identify patients who should undergo hereditary cancer surveillance and cascade testing.
Atypical placental site nodules: A Clinicopathologic study of 11 cases at an urban academic institution.
Nov 19, 2026
This retrospective study of 11 cases from an urban academic center examines the clinical presentation, pathologic features, management, and outcomes of atypical placental site nodules (APSNs), a rare and poorly characterized form of trophoblastic lesion. The authors sought to determine how APSNs present and whether they are associated with malignant gestational trophoblastic neoplasia. They found that most cases were incidentally detected, often during workup for abnormal Pap tests rather than bleeding, and none progressed to malignant GTN, suggesting APSN may be more common and clinically more benign than previously thought.
Iris metastasis as the first manifestation of metastatic endometrial adenocarcinoma.
Nov 19, 2026
This case report describes a 53-year-old woman whose severe acute anterior uveitis was the first sign of previously undiagnosed metastatic endometrial adenocarcinoma, with an iridociliary lesion that later prompted systemic workup. The authors asked whether an anterior uveal lesion could be a presumed metastasis, allowing them to avoid ocular biopsy once metastatic endometrioid adenocarcinoma was confirmed elsewhere. The lesion fully regressed after systemic oncologic treatment, supporting the conclusion that anterior uveal metastasis can rarely be the initial presentation and that multidisciplinary evaluation can enable timely diagnosis while avoiding unnecessary invasive ocular procedures.
Gestational trophoblastic neoplasia after benign curettage revealing invasive mole: a case report.
Nov 19, 2026
This case report describes a 40-year-old woman whose persistently plateaued β-hCG levels after a complete molar pregnancy prompted a repeat curettage that initially suggested a benign exaggerated placental site, despite ongoing clinical suspicion of gestational trophoblastic neoplasia (GTN). The authors ask whether management should follow clinical suspicion when pathology is discordant, and the patient ultimately underwent total laparoscopic hysterectomy, which revealed invasive mole. They conclude that GTN is primarily a clinical diagnosis guided by serial β-hCG trends rather than by pathology alone.
Beyond organ-based therapy: Genome-directed treatment of metastatic gastric-type endocervical adenocarcinoma.
Nov 19, 2026
This case report examines an 81-year-old woman with HPV-independent gastric-type endocervical adenocarcinoma and a concurrent pancreatic tail lesion, asking whether the two tumors share a clonal origin and whether genomic profiling can guide treatment. Next-generation sequencing revealed identical KRAS and TP53 alterations in both sites, supporting metastatic GEA with a pancreatic-like phenotype, and treatment with pancreatic cancer-directed gemcitabine and nab-paclitaxel produced a complete radiographic and metabolic response. The authors conclude that comparative molecular profiling may help individualize therapy in diagnostically challenging cases, though the single-patient response is hypothesis-generating and requires further study.
Unusually aggressive behavior of a usually bland and benign tumor: The story of two patients with recurrent steroid cell tumor.
Nov 19, 2026
This case report describes two patients with steroid cell tumor not otherwise specified (SCT-NOS), a rare ovarian sex cord-stromal tumor, who developed recurrences despite benign-appearing early-stage disease: one 13 years after unilateral salpingo-oophorectomy and one who died of extensive peritoneal metastases four years after cytoreductive surgery. The authors ask whether these tumors can behave unpredictably and aggressively despite bland histology, and they conclude that long-term surveillance is warranted and that molecular insights may eventually help identify at-risk patients and guide targeted therapy, since optimal management of recurrent disease remains undefined.
Familial germ cell tumors: A case of ovarian yolk sac tumor in a patient with Lynch syndrome and two brothers diagnosed with testicular seminomas.
Nov 19, 2026
This case report describes a 41-year-old woman with a stage IA ovarian yolk sac tumor, a germline pathogenic MSH6 variant (Lynch syndrome), and two brothers with testicular seminoma. The authors ask whether germ cell tumors are an under-recognized part of the Lynch syndrome spectrum, and whether the MSH6 variant or a separate familial germ cell susceptibility allele explains the clustering. They also highlight the ongoing gap in cascade genetic testing for at-risk relatives.
Potential role of antibody-drug conjugates in gynecologic cancer patients with brain metastases.
Nov 19, 2026
This retrospective case series of eight gynecologic cancer patients with brain metastases asks whether antibody-drug conjugates (ADCs), which are typically excluded from trials involving CNS disease, have meaningful intracranial activity and what toxicities they carry. Across 12 ADC regimens, 25% of intracranial responses were partial responses and 58% were stable disease, with radiation necrosis occurring in 2 of 7 patients who had received radiotherapy. The authors conclude that ADCs show feasibility and intracranial activity in this population, and they call for prospective multi-institutional trials to define ADC efficacy and the optimal sequencing of ADCs with radiotherapy.
Racial and ethnic equity in clinical trial consideration and enrollment among patients presented at gynecologic oncology tumor board.
Nov 19, 2026
This retrospective study of gynecologic oncology tumor board patients at a single New Orleans academic center (2019–2022) asked whether clinical trial consideration and enrollment differed by race or ethnicity. The authors found no statistically significant difference in enrollment between Black and Hispanic patients and white patients (p = 0.48), and other clinical, sociocultural, and social factors also did not affect enrollment. They suggest tumor boards may be an effective tool for promoting equitable access to trials, though the single-center, small-sample design limits generalizability.
Can AI support clinical decision-making in gynecologic oncology? A NCCN-guideline-based evaluation of ChatGPT and Gemini responses.
Nov 19, 2026
This study asked whether ChatGPT-4 and Gemini can give guideline-concordant answers to gynecologic oncology case vignettes, scored against 2025 NCCN guidelines by five board-certified gynecologic oncologists. Gemini showed slightly higher overall concordance than ChatGPT (mean 1.82 vs. 1.62 on a 0-2 scale), with 82% versus 64% of responses rated accurate and complete, though domain differences were nonsignificant and both models were weaker in survivorship and adjuvant treatment. The authors conclude that AI can provide largely accurate, guideline-concordant reasoning but that occasional inaccuracies require clinical oversight before use in care or patient guidance.
